Emerging evidence has revealed that KIF2A is overexpressed in tissue samples of several malignancies, such as diffuse large B cell lymphoma (DLBCL), breast cancer, and lung squamous cell carcinoma (7–9). Here, KIF2A is linked to diffuse large B-cell lymphoma.